Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106613 · ClinicalTrials.gov registry record · Phase 2
A Research Study for Patients With Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00106613 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 30 participants.
The verdict
NCT00106613, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the activity of FK228 in metastatic renal cell carcinoma (RCC) patients who have developed progressive disease (PD) following or during treatment with immunotherapy.
Interventions
- DRUG FK228 (romidepsin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-05-01 |
| Est. Completion | 2004-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00106613
The ClinicalTrials.gov registry entry for NCT00106613 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FK228 (romidepsin) is the first listed.
NCT00106613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00106613 about?
NCT00106613 is a clinical study titled "A Research Study for Patients With Metastatic Renal Cell Carcinoma". The purpose of this study is to evaluate the activity of FK228 in metastatic renal cell carcinoma (RCC) patients who have developed progressive disease (PD) following or during treatment with immunotherapy.
What is the current status of trial NCT00106613?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2003-05-01. Estimated completion is 2004-08-01.
What interventions are being tested in trial NCT00106613?
The interventions under investigation include: FK228 (romidepsin) (DRUG).
Who is sponsoring clinical trial NCT00106613?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.